PerkinElmer receives FDA EUA for respiratory SARS-CoV-2 panel

Oct. 8, 2021

The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for a respiratory panel from PerkinElmer, the company said in a news release.

The PKamp Respiratory SARS-CoV-2 RT-PCR Panel 1 assay is for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) isolated from nasopharyngeal swabs, anterior nasal swabs, and mid-turbinate swabs.

Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) that meet requirements to perform high complexity tests.

Visit PerkinElmer for more news